Trial Profile
Phase I/II Trial of Maintenance Therapy With Lenalidomide and Rituximab Following High-Dose Chemotherapy and Autologous Stem Cell Transplantation for B-cell Non-Hodgkin Lymphoma.
Status:
Discontinued
Phase of Trial:
Phase I/II
Latest Information Update: 08 Nov 2021
Price :
$35
*
At a glance
- Drugs Lenalidomide (Primary) ; Rituximab
- Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma; Mantle-cell lymphoma
- Focus Adverse reactions; Biomarker; Pharmacogenomic
- 23 Nov 2011 Actual patient number is 5 as reported by ClinicalTrials.gov.
- 23 Nov 2011 Status changed from active, no longer recruiting to discontinued as reported by ClinicalTrials.gov.
- 20 Dec 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.